We are trusted partners to our founders and co-investors. We use our deep scientific and industry networks to create exceptional value and shared success.
ETD002 is a novel TMEM16A chloride channel potentiator Therapy applicable to all cystic fibrosis patients, independent of genotype Brighton, UK, 17 August 2020: Enterprise Therapeutics Ltd (Enterprise... Novel immuno-therapies to overcome the resistance of existing cancer treatments Builds on the world-leading research into tumour associated macrophages (TAMs) Robert Haigh joins as CEO & Jane Danc...
Enterprise Therapeutics doses first subjects in Phase 1 trial for First-in-Class cystic fibrosis therapy ETD002
Macomics, an immuno-oncology company, secures £3.2 million seed funding from Epidarex Capital & the Scottish Investment Bank